Frequently asked questions
The Drug-Device Combination Products Market was valued at USD 125.6 billion in 2022.
The Drug-Device Combination Products Market is anticipated to grow at a CAGR of 9.50% between 2023 and 2030, reaching USD 237.08 billion in 2030.
Transdermal delivery systems are the leading segment in product types, holding a significant share in terms of value.
North American region is fuelling the growth of the Drug-Device Combination Products Market, with a significant share in 2022.
The top players include Medtronic plc, GlaxoSmithKline plc, Baxter International Inc., Boston Scientific Corporation, Smith & Nephew plc, Bayer AG, Novartis International AG, Becton, Dickinson and Company, Johnson & Johnson, and Abbott Laboratories.
The increasing prevalence of chronic diseases, the need for advanced treatment options, and the growing demand for personalized and targeted therapies are the major drivers of market growth.
The major market restraints are a complex regulatory landscape and stringent approval processes.
The increasing focus on patient-centric healthcare and the demand for improved patient experience and outcomes offers a significant growth opportunity for the Drug-Device Combination Products Market.
The hospital and clinic segment is leading the market growth in terms of end users.
Respiratory problems segment is leading the market growth in terms of application.